AGLE News and Press, Aeglea BioTherapeutics Inc. From 12/01/20

Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria Company eligible to receive Priority Review Voucher upon FDA approval of ACN00177 PR Newswire AUSTIN, Texas, Dec. 1, 2020 AUSTIN, Texas , ...

Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference PR Newswire AUSTIN, Texas, Nov. 24, 2020 AUSTIN, Texas , Nov. 24, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology compa...

Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences PR Newswire AUSTIN, Texas, Nov. 17, 2020 AUSTIN, Texas , Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company devel...

Aeglea BioTherapeutics (AGLE): Q3 GAAP EPS of -$0.29 beats by $0.11.Cash, cash equivalents, marketable securities and restricted cash of $141.5M.Press Release For further details see: Aeglea BioTherapeutics EPS beats by $0.11

Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177 Continued Progress in Arginase 1 Deficiency Patient Identification and Engagement Efforts ...

The FDA has designated Orphan Drug status to Aeglea BioTherapeutics' ([[AGLE]] -1.8%) to ACN00177 for the treatment of Homocystinuria, a metabolic disorder characterized by elevated plasma homocysteine which leads to a wide range of life-altering complications and reduced life expec...

Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria PR Newswire AUSTIN, Texas, Oct. 26, 2020 AUSTIN, Texas , Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a c...

Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings PR Newswire AUSTIN, Texas, Oct. 5, 2020 AUSTIN, Texas , Oct. 5, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc....

Aeglea BioTherapeutics ( AGLE +4.5% ) updated guidance on the enrollment completion of its Phase 3 PEACE trial to evaluate the safety and efficacy of pegzilarginase in patients with Arginase 1 Deficiency given the impact of COVID-19. More news on: Aeglea BioTherapeutics, Inc., H...

AUSTIN, Texas, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate ...